Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease

Abstract

This study provides Class IV evidence that in pediatric autoimmune and inflammatory CNS disorders, rituximab improves neurologic outcomes with a 7.6% risk of adverse infections.